Indivior Q1 net revenue $266M, in line; GAAP EPS $0.38, non-GAAP $0.41; FY guidance unchanged

Indivior Pharmaceuticals, Inc.

2025-Q1 EPS reported $0.38 revenue$266,000,000

Net revenue $266M (-6% YoY), in line with expectations; U.S. net revenue $222M (-8%).
SUBLOCADE NR $176M (-2% YoY); FY 2025 guidance unchanged at $725M-$765M.
GAAP diluted EPS $0.38 (down 15%); non-GAAP diluted EPS $0.41 (down 2%).
SG&A $132M (-8% YoY non-GAAP) reflects cost savings; FY non-GAAP SG&A guided $525M-$535M.
Revised prior financials to correct Branded Fee accrual (immaterial $6M overstatement in 2024).

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-25-091736
form_type: 8-K
ticker: INDV
cik: 0001625297
company_name: Indivior Pharmaceuticals, Inc.
filed_at: 2025-04-24T23:59:59+00:00
discovered_at: 2026-05-14T18:02:49.104625+00:00
generated_at: 2026-05-23T07:04:18.575385+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.5
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-25-091736
json_url: https://secwatch.observer/filing/0001193125-25-091736.json
markdown_url: https://secwatch.observer/filing/0001193125-25-091736.md
text_url: https://secwatch.observer/filing/0001193125-25-091736.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1625297/000119312525091736/0001193125-25-091736-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1625297/000119312525091736/d926381d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-25-091736

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.